Phase III clinical trial

Greenwich LifeSciences' GLSI-100 breast cancer immunotherapy receives ASCO 2026 abstract acceptance, showing 70-80% recurrence reduction in Phase III trial.

$GLSI receives Nasdaq compliance notice for late Form 10-K filing; stock remains tradable as company works with auditors on submission.

Greenwich LifeSciences expands GLSI-100 breast cancer therapy addressable market by 100% through new patent claims extending to 2045, adding 88,000 potential patients annually.

Class action filed against $UGXY alleging misleading statements about Phase III Orbit study for rare bone disease treatment. Investors may recover losses from August 2023 forward.

Greenwich LifeSciences expands FLAMINGO-01 trial with City of Hope, growing sites to 190-200. Preliminary data shows 70-80% recurrence reduction in breast cancer immunotherapy study.

$GLSI's GLSI-100 immunotherapy demonstrates 70-80% recurrence reduction in Phase III trial data accepted for AACR presentation.

Greenwich LifeSciences deploys commercially manufactured GP2 across all 40 FLAMINGO-01 trial sites following FDA approval, scaling production capacity significantly.

Class action lawsuit filed against $UGDX alleging false statements about setrusumab efficacy for Osteogenesis Imperfecta, claiming Phase III results overstated drug benefits.

Greenwich LifeSciences boosts FLAMINGO-01 screening by 33% to 800 patients yearly, with non-HLA-A*02 arm fully enrolled and showing 80% recurrence reduction.

Greenwich LifeSciences presents FLAMINGO-01 Phase III trial data at AACR 2026, showing 80% recurrence reduction. Non-HLA-A*02 arm fully enrolled with 250 patients.